跳至主要内容
临床试验/NCT04744818
NCT04744818已完成不适用

Effects of Iron Supplementation on Pediatric Vaccine Response

Jessica Rigutto3 个研究点 分布在 2 个国家目标入组 288 人开始时间: 2021年2月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
288
试验地点
3
主要终点
Pertussis antibody profile

研究概览

简要总结

ID/IDA affects many young children in Africa. Vaccines provide tremendous benefits in LMIC; however, they currently fail to reach their full potential. We need to better understand the causes of vaccine failure, in order to develop new strategies to improve vaccine immunogenicity.

This study will contribute to children's health by: (1) providing updated guidelines to better define the prevalence of ID/IDA in early infancy, and its safe and effective control using iron; and (2) providing a new approach to improve response to pediatric vaccines in LMIC, by ensuring adequate iron status at time of vaccination.

详细描述

Two major pediatric public health goals in LMIC are increasing immunization effectiveness and reducing ID/IDA in children. ID/IDA affects many young children in Africa. Current guidelines do not recommend routine testing of hemoglobin in early infancy, as it is generally believed that most infants are born with adequate iron stores to last 6 months. However, many African infants are born with low iron stores and ID/IDA may develop earlier than generally appreciated, within 2-3 months after birth. Vaccines provide tremendous benefits in LMIC; however, they currently fail to reach their full potential. We need to better understand the causes of vaccine failure, in order to develop new strategies to improve vaccine immunogenicity. Despite lower efficacy in LMIC, these vaccines provide a major benefit because the disease burden is so high; however, if approaches can be found to improve immunogenicity, these vaccines would be even more powerful.

For this study, 6 weeks old infants will be randomly assigned to two study groups. Group 1 will receive iron at time of pediatric vaccinations from age 6-24 weeks. Group 2 will receive no iron at time of pediatric vaccinations. All infants will receive a multivitamin syrup from age 6-24 weeks. All infants remaining ID/IDA at age 24 weeks will receive iron. Infants will be followed-up until age 52 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
39 Days 至 45 Days(Child)
性别
All
接受健康志愿者

入选标准

  • Mother at least ≥15 years of age.
  • 6 weeks (+/- 3 days) of age
  • Iron deficient (erythrocyte zinc protoporphyrin (ZnPP) >61 μmol/mol heme)
  • With or without anemia, but not severely anemic (Hb >70 g/L)
  • No malaria
  • No medical condition that precludes study involvement
  • Mother HIV negative
  • Vaginal delivery
  • No iron supplementation prior to study enrolment
  • Not wasted (length for height z score of ≥-2)
  • Not underweight (weight for age z score ≥-2)
  • From the hospital record, term or late preterm delivery (≥34 weeks)
  • Full-time breastfed at least until the screening
  • No vaccines beyond the birth dose of OPV and BCG prior to enrolment

排除标准

  • 未提供

结局指标

主要结局

Pertussis antibody profile

时间窗: from 6 to 24 weeks

Diphtheria antibody profile

时间窗: from 6 to 24 weeks

次要结局

  • antiviral immunoglobulin G response(24 weeks of age)
  • Proteomics(52 weeks of age)
  • Hemoglobin(52 weeks of age)
  • Alpha-glycoprotein(52 weeks of age)
  • Haemophilus influenzae b antibody profile(from 6 to 24 weeks)
  • Rotavirus antibody profile(from 6 to 24 weeks)
  • Anti-vaccine antibody titers(52 weeks of age)
  • Anti-vaccine seroconversion(52 weeks of age)
  • Anti-vaccine antibody avidity index(52 weeks of age)
  • infant antiviral immunoglobulin G response(52 weeks of age)
  • Calprotectin(24 weeks of age)
  • C-reactive protein(52 weeks of age)
  • Tetanus antibody profile(from 6 to 24 weeks)
  • immune cell populations(52 weeks of age)
  • Plasma ferritin(52 weeks of age)
  • Polio antibody profile(from 6 to 24 weeks)
  • soluble transferrin receptor(52 weeks of age)
  • Transcriptomics(24 weeks of age)
  • Intestinal fatty acid binding protein(24 weeks of age)
  • Plasma iron(52 weeks of age)
  • Pneumococcus antibody profile(from 6 to 24 weeks)

研究者

发起方
Jessica Rigutto
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Jessica Rigutto

Dr. Nicole Stoffel

Swiss Federal Institute of Technology

研究点 (3)

Loading locations...

相似试验